上海海利生物技术股份有限公司 章 程 第一条 为确立上海海利生物技术股份有限公司（以下简称"公司"）的法律 地位，维护公司、股东、职工和债权人的合法权益，规范公司的组织和行为，使 之形成自我发展，自我约束的良好运行机制，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）及有 关法律、法规的规定，制定本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司。 公司是经上海市商务委员会沪商外资批〔2011〕3969 号文批准，由上海海 利生物药品有限公司的 8 家股东作为发起人，在上海海利生物药品有限公司基础 上依法变更设立的。公司在上海市市场监督管理局注册登记，取得营业执照，营 业执照统一社会信用代码为：9131000013413459XC。 第三条 公司于 2015 年 4 月 23 日经中华人民共和国证券监督管理委员会（以 下简称"中国证监会"）证监许可〔2015〕710 号文件核准，首次向社会公众发行 人民币普通股 7,000 万股，于 2015 年 5 月 15 日在上海证券交易所（以下简称"证 券交易所"）上市。 第四条 公司注册 ...

Group 1 - The company's Q3 revenue is 39.9651 million yuan, a decrease of 40.20% [1] - The net profit for Q3 is 2.0948 million yuan, a decrease of 58.51% [1] - The company's revenue for the first three quarters is 150 million yuan, a decrease of 14.15% [1] Group 2 - The net profit for the first three quarters is 20.3297 million yuan, an increase of 0.77% [1]

证券代码：603718 证券简称：海利生物 公告编号：2025-045 上海海利生物技术股份有限公司 关于对上海证券交易所《关于上海海利生物技术股份有 限公司 2025 年半年度报告的信息披露监管问询函》的回 复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 2025 年 9 月 29 日，上海海利生物技术股份有限公司（以下简称"公司""上 市公司"或"海利生物"）收到上海证券交易所上市公司管理一部下发的《关于上 海海利生物技术股份有限公司 2025 年半年度报告的信息披露监管问询函》（上证公 函【2025】1407 号）（以下简称"问询函"）。根据《问询函》的要求，公司对《问 询函》所列事项逐一复核落实，现就《问询函》所列事项进行逐项回复并说明如下。 本回复的字体代表以下含义： | 字体 | 含义 | | --- | --- | | 黑体（加粗） | 问询函所列问题 | | 宋体 | 对问询函所列问题的回复及说明 | 本问询函回复中，若出现总数与各分项数值之和尾数不符的情况，均为四舍五 入原因造成。 问题 1：关 ...

Core Viewpoint - The animal health sector experienced a slight increase of 0.21% on October 24, with significant contributions from specific stocks, particularly Biological Shares, which led the gains [1] Market Performance - The Shanghai Composite Index closed at 3950.31, up 0.71% - The Shenzhen Component Index closed at 13289.18, up 2.02% [1] Stock Performance in Animal Health Sector - Biological Shares (600201) closed at 10.77, up 2.87% with a trading volume of 311,900 shares and a turnover of 333 million yuan - Other notable stocks include: - *ST Green Health (002868): closed at 29.09, up 0.66% - Shunlian Biological (688098): closed at 10.75, up 0.66% - Huisheng Biological (300871): closed at 20.75, up 0.48% - Yongshun Biological (920729): closed at 9.68, up 0.31% - Jinhe Biological (002688): closed at 6.68, unchanged [1] Capital Flow Analysis - The animal health sector saw a net inflow of 8.6031 million yuan from institutional investors, while retail investors experienced a net outflow of 24.4195 million yuan [2] - The breakdown of capital flow indicates: - Repu Biological (300119) had a net inflow of 9.2707 million yuan from institutional investors - Biological Shares (600201) saw a net inflow of 8.4244 million yuan - Kexin Biological (688526) had a net inflow of 5.4428 million yuan from institutional investors [3]

Group 1 - The core viewpoint of the news highlights the recent trading performance and financial metrics of Haili Biological, indicating a slight increase in stock price and a net financing outflow on October 22 [1] - On October 22, Haili Biological's stock price rose by 0.28%, with a trading volume of 31.17 million yuan. The financing buy-in amount was 4.60 million yuan, while the financing repayment was 5.52 million yuan, resulting in a net financing outflow of 0.92 million yuan [1] - As of October 22, the total margin balance for Haili Biological was 219 million yuan, with the financing balance accounting for 4.79% of the circulating market value, which is below the 30th percentile level over the past year, indicating a low level of financing [1] Group 2 - As of June 30, Haili Biological had 31,500 shareholders, an increase of 0.14% from the previous period, while the average circulating shares per person decreased by 0.14% to 20,569 shares [2] - For the first half of 2025, Haili Biological reported an operating income of 110 million yuan, representing a year-on-year growth of 2.02%, and a net profit attributable to shareholders of 18.23 million yuan, which is a 20.56% increase year-on-year [2] - Haili Biological has distributed a total of 209 million yuan in dividends since its A-share listing, with 107 million yuan distributed over the past three years [3]

Core Viewpoint - The animal health sector experienced a decline of 0.36% on October 22, with Dayu Biological leading the drop. The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1]. Stock Performance Summary - The following stocks in the animal health sector showed varied performance: - Shengwu Co. (600201) closed at 10.78, up 0.56% with a trading volume of 327,000 shares and a turnover of 351 million yuan - Ruipu Biological (300119) closed at 21.50, up 0.51% with a trading volume of 73,200 shares and a turnover of 158 million yuan - Haili Biological (603718) closed at 7.04, up 0.28% with a trading volume of 44,200 shares and a turnover of 31.17 million yuan - Dayu Biological (920970) closed at 9.46, down 1.25% with a trading volume of 20,800 shares and a turnover of 19.89 million yuan - ST Lvkang (002868) closed at 28.49, down 1.18% with a trading volume of 9,904 shares and a turnover of 28.26 million yuan [1][2]. Capital Flow Analysis - The animal health sector saw a net outflow of 47.45 million yuan from institutional investors, while retail investors contributed a net inflow of 36.66 million yuan. Speculative funds recorded a net inflow of 10.80 million yuan [2][3]. - Specific stock capital flows included: - Shunlian Biological (688098) had a net inflow of 6.94 million yuan from institutional investors but a net outflow of 12.58 million yuan from retail investors - Ruipu Biological (300119) experienced a net outflow of 2.94 million yuan from institutional investors, with a significant net inflow of 13.74 million yuan from speculative funds [3].

Core Viewpoint - The animal health sector experienced a slight decline of 0.02% on October 21, with Bioworks leading the drop. Meanwhile, the Shanghai Composite Index rose by 1.36% and the Shenzhen Component Index increased by 2.06% [1]. Group 1: Market Performance - The animal health sector's performance was mixed, with individual stocks showing varying degrees of increase and decrease. Notably, the top gainers included: - Driving Force (4.50% increase) [1] - Dayu Biological (3.46% increase) [1] - Yongshun Biological (2.06% increase) [1] - Conversely, Bioworks saw a decline of 2.10%, leading the losses in the sector [2]. Group 2: Trading Volume and Capital Flow - The trading volume for the animal health sector indicated a net outflow of 151 million yuan from institutional investors, while retail investors saw a net inflow of 116 million yuan [2]. - The capital flow for individual stocks showed significant movements, with: - Key stock, Bioworks, experiencing a net outflow of 6.46 million yuan from institutional investors [3]. - Retail investors contributed a net inflow of 7.59 million yuan to Zhongmu Co. [3]. Group 3: Individual Stock Analysis - The following stocks had notable capital flows: - KQ Biological had a net inflow of 1.83 million yuan from institutional investors [3]. - ST Green Health faced a net outflow of 4.37 million yuan from institutional investors [3]. - The stock of Rui Pu Biological saw a net inflow of 17.22 million yuan from retail investors despite a net outflow from institutional investors [3].

Market Overview - The animal health sector increased by 0.81% on October 20, with Xianfeng Holdings leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Stock Performance - Xianfeng Holdings (002141) closed at 4.06, up 5.45% with a trading volume of 588,700 shares and a turnover of 237 million yuan [1] - Other notable stocks included ST Lvkang (002868) at 28.36, up 5.00%, and Biological Shares (600201) at 10.95, up 1.48% [1] - The overall trading volume and turnover for the animal health sector were significant, indicating active market participation [1] Capital Flow - The animal health sector saw a net inflow of 31.5863 million yuan from institutional investors, while retail investors experienced a net outflow of 10.9434 million yuan [2] - The main capital inflow was primarily directed towards Xianfeng Holdings, which had a net inflow of 28.5381 million yuan [3] - Conversely, stocks like Shunlian Biological (688088) and ST Lvkang experienced net outflows from retail investors, indicating a shift in investor sentiment [3]

Core Insights - The animal health sector experienced a decline of 0.28% on October 17, with Ruipu Biotech leading the drop [1][2] - The Shanghai Composite Index closed at 3839.76, down 1.95%, while the Shenzhen Component Index closed at 12688.94, down 3.04% [1] Stock Performance - Shenyuan Biological (688088) saw a significant increase of 10.65%, closing at 11.43 with a trading volume of 319,600 shares and a turnover of 368 million yuan [1] - Other notable gainers included Yongshun Biological (920729) with a rise of 2.94% and Xianfeng Holdings (002141) with an increase of 1.85% [1] - Conversely, Ruipu Biotech (300119) fell by 2.47%, closing at 21.69 with a trading volume of 109,100 shares and a turnover of 239 million yuan [2] Capital Flow - The animal health sector saw a net inflow of 33.17 million yuan from institutional investors, while retail investors experienced a net outflow of 37.18 million yuan [2][3] - Shenyuan Biological had a net inflow of 76.52 million yuan from institutional investors, representing 20.82% of its trading volume [3] - In contrast, other companies like XD Plai Ke (603566) and Huayi Biological (603718) faced significant net outflows from both institutional and retail investors [3]

Core Viewpoint - The animal health sector experienced a decline of 0.85% on October 16, with Xianfeng Holdings leading the drop. The Shanghai Composite Index rose by 0.1%, while the Shenzhen Component Index fell by 0.25 [1]. Group 1: Market Performance - The closing price of *ST Lvkang was 27.48, with an increase of 5.01%, while other stocks in the sector showed mixed results [1]. - The total trading volume for the animal health sector was significant, with *ST Lvkang recording a volume of 14,900 hands and a transaction amount of 40.81 million yuan [1]. - The overall market saw a net outflow of 126 million yuan from the animal health sector, with retail investors contributing a net inflow of 91.62 million yuan [2]. Group 2: Individual Stock Analysis - *ST Lvkang had a net inflow of 5.23 million yuan from major funds, while Xianfeng Holdings saw a net outflow of 3.36 million yuan [3]. - The stock of RuiPu Bio had a significant net outflow of 25.44 million yuan from major funds, despite a retail net inflow of 39.62 million yuan [3]. - The stock of HaiLi Bio experienced a net outflow of 4.47 million yuan from major funds, with a retail net inflow of 2.64 million yuan [3].